Breaking Finance News

Liberum Capital disclosed AstraZeneca PLC (LON:AZN), boosting its price target to 5,000.00GBX earlier today

Stating a potential upside of 0.02%, Liberum Capital upped the price target of AstraZeneca PLC (LON:AZN) to 5,000.00GBX

Previously on 9/13/2017, Societe Generale reported about AstraZeneca PLC (LON:AZN) held steady the target price at 7,600.00GBX. At the time, this indicated a possible upside of 0.58%.

Yesterday AstraZeneca PLC (LON:AZN) traded -1.61% lower at 4,887.50GBX. The company’s 50-day moving average is 4,574.38GBX and its 200-day moving average is 4,882.27GBX. The last stock close price is up -0.75% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 2,352,977 shares of the stock were exchanged, up from an average trading volume of 2,257,290

See Chart Below

AstraZeneca PLC (LON:AZN)

AstraZeneca PLC has a 52 week low of 3,996.00GBX and a 52 week high of 5,520.00GBX with a P/E ratio of 15.89 The company’s market cap is currently 0 GBX.

In addition to Liberum Capital reporting its target price, a total of 29 firms have reported on the stock. The consensus target price is 61.96GBX with 4 firms rating the stock a strong buy, 14 firms rating the stock a buy, 13 firms rating the stock a hold, 2 firms rating the stock a underperform, and finally 1 firm rating the stock a sell.

About AstraZeneca PLC (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.